NervGen doses first participant in Phase 3 RESTORE study of NVG-291 for chronic spinal cord injury

NervGen announced it has dosed the first participant in RESTORE, a Phase 3 registrational study evaluating NVG-291 in chronic spinal cord injury. Enrollment completion is expected in H2 2027, with topline data in H1 2028.

Detected & updated continuously · Source: Nebula